1. Innovative Drugs (Orphan Drugs included): New molecular entity; new structure, target; new therapies in accordance with drug administration; modified new drugs with clinical value (prodrugs, drugs with new component, dosage forms, new indication or routes of administration);
2. Class II or Class III Medical Devices and Diagnostic Regent with obvious product superiority and authorized approval for clinical trial;
3. Artificial Intelligence (AI), Innovation R&D Services, WIT-MED + Big Data.
Important: For clinical data release, only Type I application will be accepted.